{"log_id": 8630428672152692827, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.007684, "average": 0.97529, "min": 0.574409}, "location": {"width": 850, "top": 136, "height": 54, "left": 190}, "words": "先前HBV感染情况进行评价。尚不明确依那西普和HBV激活的因果关系,已确诊为HBV"}, {"probability": {"variance": 0, "average": 0.999311, "min": 0.999311}, "location": {"width": 31, "top": 139, "height": 28, "left": 1177}, "words": "局"}, {"probability": {"variance": 0.000149, "average": 0.996231, "min": 0.92318}, "location": {"width": 852, "top": 186, "height": 52, "left": 188}, "words": "携带者的患者使用依那西普时,应谨慎使用。如果HBV携带者使用依那西普治疗,应监"}, {"probability": {"variance": 0.00678, "average": 0.979534, "min": 0.572}, "location": {"width": 565, "top": 243, "height": 45, "left": 190}, "words": "测HBV感染激活的体征和症状,必要时应采取恰当的治疗"}, {"probability": {"variance": 7e-06, "average": 0.998544, "min": 0.992721}, "location": {"width": 139, "top": 306, "height": 27, "left": 189}, "words": "丙型肝炎恶化"}, {"probability": {"variance": 2e-06, "average": 0.998911, "min": 0.994363}, "location": {"width": 811, "top": 335, "height": 52, "left": 236}, "words": "曾有使用依那西普治疗的患者出现丙型肝炎恶化的报告,但是尚不明确依那西普和"}, {"probability": {"variance": 1.3e-05, "average": 0.997468, "min": 0.987504}, "location": {"width": 255, "top": 400, "height": 36, "left": 187}, "words": "丙型肝炎恶化的因果关系"}, {"probability": {"variance": 4e-06, "average": 0.998627, "min": 0.994687}, "location": {"width": 231, "top": 453, "height": 30, "left": 188}, "words": "糖尿病患者的低血糖症"}, {"probability": {"variance": 3.2e-05, "average": 0.998298, "min": 0.966674}, "location": {"width": 817, "top": 485, "height": 49, "left": 233}, "words": "曾有患者使用糖尿病治疗药物后使用依那西普治疗出现低血糖症的报告,其中一些患者"}, {"probability": {"variance": 0, "average": 0.999496, "min": 0.997594}, "location": {"width": 310, "top": 548, "height": 37, "left": 188}, "words": "不得不减少使用抗糖尿病的药物"}, {"probability": {"variance": 3e-06, "average": 0.998264, "min": 0.994442}, "location": {"width": 324, "top": 596, "height": 37, "left": 189}, "words": "依那西普和阿那白滞素联合治疗"}, {"probability": {"variance": 1e-05, "average": 0.998169, "min": 0.986145}, "location": {"width": 815, "top": 632, "height": 50, "left": 236}, "words": "与单独使用依那西普相比,依那西普和阿那白滞素联合治疗与严重感染和中性粒细"}, {"probability": {"variance": 7.8e-05, "average": 0.997432, "min": 0.944889}, "location": {"width": 865, "top": 682, "height": 50, "left": 187}, "words": "胞减少风险增高相关。并未证实这种联合疗法可以增加临床效果。因此不推荐依那西普"}, {"probability": {"variance": 0.004318, "average": 0.980522, "min": 0.639777}, "location": {"width": 632, "top": 736, "height": 46, "left": 198}, "words": "和阿那白滞素联合使用(参见“药物相互作用”和“不良反应”)"}, {"probability": {"variance": 5e-06, "average": 0.997453, "min": 0.991717}, "location": {"width": 301, "top": 793, "height": 37, "left": 189}, "words": "依那西普和阿巴他塞联合治疗"}, {"probability": {"variance": 1.8e-05, "average": 0.998616, "min": 0.974398}, "location": {"width": 819, "top": 830, "height": 47, "left": 237}, "words": "在临床研究中,依那西普和阿巴他塞联合治疗导致严重不良事件的发生率增加,并"}, {"probability": {"variance": 2.3e-05, "average": 0.998173, "min": 0.97603}, "location": {"width": 576, "top": 886, "height": 40, "left": 187}, "words": "未证实这种联合疗法可以增加临床效果,因此不推荐使用"}, {"probability": {"variance": 0, "average": 0.999748, "min": 0.999605}, "location": {"width": 97, "top": 945, "height": 28, "left": 189}, "words": "变态反应"}, {"probability": {"variance": 3.6e-05, "average": 0.998125, "min": 0.963538}, "location": {"width": 817, "top": 977, "height": 47, "left": 236}, "words": "常有报道与依那西普使用相关的变态反应。变态反应包括血管性水肿和荨麻疹,严"}, {"probability": {"variance": 1.1e-05, "average": 0.998419, "min": 0.983119}, "location": {"width": 869, "top": 1027, "height": 46, "left": 188}, "words": "重的此类反应曾有发生。如果出现任何重度的变态或过敏反应,必须立即停止使用依那"}, {"probability": {"variance": 0, "average": 0.999341, "min": 0.998109}, "location": {"width": 231, "top": 1088, "height": 32, "left": 188}, "words": "西普并进行适当的治疗"}, {"probability": {"variance": 1e-06, "average": 0.998247, "min": 0.997303}, "location": {"width": 97, "top": 1138, "height": 28, "left": 189}, "words": "免疫抑制"}, {"probability": {"variance": 0.064977, "average": 0.748778, "min": 0.395139}, "location": {"width": 93, "top": 1144, "height": 34, "left": 734}, "words": "海医"}, {"probability": {"variance": 9.5e-05, "average": 0.99718, "min": 0.939415}, "location": {"width": 822, "top": 1173, "height": 45, "left": 236}, "words": "由于肿瘤坏死因子(TNF)可以介导炎症反应并调节细胞免疫反应,所以TNF抑"}, {"probability": {"variance": 0.000185, "average": 0.994385, "min": 0.943532}, "location": {"width": 873, "top": 1223, "height": 42, "left": 186}, "words": "制剂(包括依那西普)会影响患者对感染和恶性肿瘤的抵抗力。在一项对49名接受依"}, {"probability": {"variance": 4e-06, "average": 0.998958, "min": 0.988718}, "location": {"width": 871, "top": 1272, "height": 42, "left": 186}, "words": "那西普治疗的类风湿关节炎患者的研究中,无证据显示其可能抑制迟发性超敏反应,免"}, {"probability": {"variance": 3e-06, "average": 0.998892, "min": 0.993863}, "location": {"width": 423, "top": 1327, "height": 36, "left": 185}, "words": "疫球蛋白水平降低或效应细胞群计数改变"}, {"probability": {"variance": 0.002999, "average": 0.988663, "min": 0.665551}, "location": {"width": 817, "top": 1372, "height": 39, "left": 234}, "words": "当患者明显暴露于水痘-带状疱疹病毒时应暂停使用依那西普,并应考虑使用水痘"}, {"probability": {"variance": 0, "average": 0.999553, "min": 0.997791}, "location": {"width": 304, "top": 1429, "height": 30, "left": 184}, "words": "带状疱疹免疫球蛋白预防治疗"}, {"probability": {"variance": 8e-06, "average": 0.998368, "min": 0.986633}, "location": {"width": 699, "top": 1471, "height": 38, "left": 231}, "words": "在免疫抑制或者慢性感染患者中依那西普的安全性和有效性尚不明确"}, {"probability": {"variance": 3e-06, "average": 0.998652, "min": 0.993124}, "location": {"width": 332, "top": 1525, "height": 32, "left": 183}, "words": "恶性肿瘤和淋巴组织增殖性疾病"}, {"probability": {"variance": 1e-06, "average": 0.999368, "min": 0.996634}, "location": {"width": 828, "top": 1567, "height": 39, "left": 232}, "words": "上市后曾有侵犯不同部位的恶性肿瘤的报告(包括乳腺癌、肺癌和淋巴瘤)(参见"}, {"probability": {"variance": 0.00908, "average": 0.956368, "min": 0.661748}, "location": {"width": 157, "top": 1627, "height": 26, "left": 183}, "words": "版本号:2009011"}, {"probability": {"variance": 3.2e-05, "average": 0.995032, "min": 0.986718}, "location": {"width": 177, "top": 1618, "height": 27, "left": 798}, "words": "第11页共31页"}], "language": 3}